Eileen M O'Reilly MD; ASCO 2026: RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study

Eileen M O'Reilly MD; ASCO 2026: RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study

June 1, 2026 · 13 min

About this episode

Eileen M O'Reilly MD discusses the promising results of the RASolute 302 Study presented at ASCO 2026, highlighting the drug Daraxonrasib's impact on survival rates in pancreatic cancer patients.

Standing ovation at ASCO for RASolute 302 Study

People in this episode

Guest: Eileen M O'Reilly MD

Topics covered

Keywords

Mentioned in this episode

Organizations: ASCO

Products: Daraxonrasib

Places: Pancreas Cancer

More episodes of Audio Journal of Oncology Podcast

Explore listener stats, chart rankings, contacts and more on the Audio Journal of Oncology Podcast podcast page.